Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Join | Sign in
Home>Videos>This Video
  Videos

Return

Bio-Rad Droplet Digital™ PCR and Organ Transplant Rejection
Bio-Rad Laboratories

Researchers at Chronix Biomedical applied Bio-Rad's ddPCR™ technology to quantify graft-derived cell-free DNA (cfDNA) in recent liver transplant patients and in stable patients who had undergone a transplant procedure more than six months earlier. ddPCR technology allowed Chronix to develop a fast and cost-effective laboratory test to detect cfDNA released into the blood stream by dying cells from the transplanted organ.

Sequencing methods typically require batch sampling, but using ddPCR assays, researchers are able to run single samples. Additionally, this method reduces test time from three days or more to one day, and reduces costs by 90 percent. The study authors were able to address the need for donor DNA by preselecting single-nucleotide polymorphisms (SNPs) that ensure enough heterogeneity between donor and recipient. The new blood test can also deliver results up to several days earlier than the conventional aspartate aminotransferase (AST) and bilirubin tests for liver transplantation rejection, with the potential for an immediate positive impact on patient care.

Chronix Biomedical is a molecular diagnostics company developing blood tests primarily for cancer, including companion diagnostics and tests for detecting minimal residual disease. Chronix is preparing to offer its pioneering tests through its own laboratories under CLIA certification in North America and the CE mark in Europe. The Company's initial product is a test to be used by cancer treatment centers and oncologists in the treatment of breast cancer patients. Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany and Brookings, South Dakota.

The Droplet Digital PCR system enables the quantification of target DNA with unrivaled precision by partitioning samples into 20,000 nanoliter-sized droplets. After PCR on a thermal cycler, PCR-positive and PCR-negative droplets are counted to provide absolute quantification of the target DNA. The QX200™ system, Bio-Rad's second-generation digital PCR system, provides absolute quantification of target DNA or RNA molecules using EvaGreen or TaqMan hydrolysis probes, yielding unmatched sensitivity and precision for a wide variety of applications.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
Ground-Breaking Lung Cancer Breath Test In Clinical Trial
University of Leicester and Leicester’s Hospitals to evaluate revolutionary device which detects lung cancer in early stages.
Saliva Test to Diagnose Autism
A spit test may one day be able to diagnose autism according to researchers at Clarkson University and the State University of New York at Plattsburgh.
Paper Test for Ebola
Prototype is designed to detect diseases and deliver real-time epidemiological data.
New €25 Blood Test A Breakthrough In The Diagnosis Of Bowel Cancer
New blood test will spot bowel cancer at earliest stage, removing the need for ‘unpleasant’ faecal screens.
New Biomarkers To Spot Pancreatic Cancer Early
A combination of two biomarkers can identify pre-clinical pancreatic cancer.
NIH Launches Tool to Advance Down Syndrome Research
Web portal will help approved professionals to plan clinical studies.
New Blood Test For Aggressive Bone Cancer
Researchers at the University of East Anglia are developing a simple blood test to diagnose bone cancer thanks to funding from the Big C.
Novel Approach to Visualize & Measure Protein Complexes in Tumors
Moffitt Cancer Center researchers have developed a PLA to analyze biological processes occurring within tumors.
Prognostic Test for E2F4 in Breast Cancer Developed
A gene signature in E2F4 has been identified which is predictive of estrogen receptor positive breast cancer.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters